IMMUNOVANT, INC. (IMVT) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Win.
27/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinIMVT / S&P 55.11% / 15.20% |
LoseIMVT / S&P IMVT unavailable / 15.00% |
LoseIMVT / S&P -0.70% / 50.40% |
| 2026-Q11/3 |
WinIMVT / S&P -2.28% / -4.33% |
LoseIMVT / S&P IMVT unavailable / 11.30% |
LoseIMVT / S&P 1.83% / 27.70% |
| 2025-Q41/3 |
WinIMVT / S&P 57.69% / 2.65% |
LoseIMVT / S&P IMVT unavailable / 9.00% |
LoseIMVT / S&P 2.29% / 13.40% |
| 2025-Q31/3 |
LoseIMVT / S&P 0.75% / 8.12% |
LoseIMVT / S&P IMVT unavailable / 4.61% |
WinIMVT / S&P 27.48% / 13.45% |
| 2025-Q21/3 |
LoseIMVT / S&P -6.38% / 10.94% |
LoseIMVT / S&P IMVT unavailable / 4.83% |
WinIMVT / S&P 47.15% / 10.63% |
| 2025-Q11/3 |
LoseIMVT / S&P -31.01% / -4.27% |
LoseIMVT / S&P IMVT unavailable / 4.98% |
WinIMVT / S&P 43.68% / 10.57% |
| 2024-Q41/3 |
LoseIMVT / S&P -13.12% / 2.41% |
LoseIMVT / S&P IMVT unavailable / 5.25% |
WinIMVT / S&P 43.17% / 6.15% |
| 2024-Q32/3 |
WinIMVT / S&P 7.99% / 5.89% |
LoseIMVT / S&P IMVT unavailable / 5.89% |
WinIMVT / S&P 13.27% / 6.11% |
| 2024-Q20/3 |
LoseIMVT / S&P -18.29% / 4.28% |
LoseIMVT / S&P IMVT unavailable / 5.38% |
LoseIMVT / S&P 0.52% / 5.12% |
| 2024-Q11/3 |
LoseIMVT / S&P -23.31% / 10.56% |
LoseIMVT / S&P IMVT unavailable / 5.71% |
WinIMVT / S&P 11.76% / 5.59% |
| 2023-Q41/3 |
LoseIMVT / S&P 9.74% / 11.69% |
LoseIMVT / S&P IMVT unavailable / 6.81% |
WinIMVT / S&P 10.24% / 7.78% |
| 2023-Q32/3 |
WinIMVT / S&P 102.37% / -3.27% |
LoseIMVT / S&P IMVT unavailable / 7.52% |
WinIMVT / S&P 28.10% / -5.03% |
| 2023-Q22/3 |
WinIMVT / S&P 22.31% / 8.74% |
LoseIMVT / S&P IMVT unavailable / 9.50% |
WinIMVT / S&P 30.61% / -8.57% |
| 2023-Q11/3 |
LoseIMVT / S&P -12.62% / 7.50% |
LoseIMVT / S&P IMVT unavailable / 10.77% |
WinIMVT / S&P 18.88% / -15.69% |
| 2022-Q42/3 |
WinIMVT / S&P 218.10% / 7.56% |
LoseIMVT / S&P IMVT unavailable / 11.88% |
WinIMVT / S&P 27.69% / -17.99% |
| 2022-Q32/3 |
WinIMVT / S&P 43.08% / -4.88% |
LoseIMVT / S&P IMVT unavailable / 13.47% |
WinIMVT / S&P 21.43% / -1.41% |
| 2022-Q21/3 |
LoseIMVT / S&P -29.22% / -16.10% |
LoseIMVT / S&P IMVT unavailable / 13.71% |
WinIMVT / S&P 26.72% / 11.04% |
| 2022-Q10/3 |
LoseIMVT / S&P -35.33% / -4.60% |
LoseIMVT / S&P IMVT unavailable / 15.97% |
LoseIMVT / S&P 16.26% / 42.23% |
| 2021-Q40/3 |
LoseIMVT / S&P -1.96% / 11.03% |
LoseIMVT / S&P IMVT unavailable / 15.00% |
LoseIMVT / S&P IMVT unavailable / 96.40% |
| 2021-Q30/3 |
LoseIMVT / S&P -17.79% / 0.58% |
LoseIMVT / S&P IMVT unavailable / 10.77% |
LoseIMVT / S&P IMVT unavailable / 69.42% |
| 2021-Q20/3 |
LoseIMVT / S&P -34.10% / 8.55% |
LoseIMVT / S&P IMVT unavailable / 6.58% |
LoseIMVT / S&P IMVT unavailable / 51.81% |
| 2021-Q10/3 |
LoseIMVT / S&P -65.27% / 6.17% |
LoseIMVT / S&P IMVT unavailable / -1.06% |
LoseIMVT / S&P IMVT unavailable / 7.39% |
| 2020-Q41/3 |
WinIMVT / S&P 31.26% / 12.15% |
LoseIMVT / S&P IMVT unavailable / -3.72% |
LoseIMVT / S&P IMVT unavailable / -33.42% |
| 2020-Q31/3 |
WinIMVT / S&P 44.52% / 8.93% |
LoseIMVT / S&P IMVT unavailable / -2.04% |
LoseIMVT / S&P IMVT unavailable / -27.10% |
| 2020-Q21/3 |
WinIMVT / S&P 56.44% / 20.54% |
LoseIMVT / S&P IMVT unavailable / -0.46% |
LoseIMVT / S&P IMVT unavailable / -27.11% |
| 2020-Q11/3 |
WinIMVT / S&P -1.92% / -19.60% |
LoseIMVT / S&P IMVT unavailable / 3.47% |
LoseIMVT / S&P IMVT unavailable / -14.75% |
| 2019-Q41/3 |
WinIMVT / S&P 58.38% / 9.07% |
LoseIMVT / S&P IMVT unavailable / 5.36% |
LoseIMVT / S&P IMVT unavailable / 2.99% |
| 2019-Q31/3 |
WinIMVT / S&P 2.24% / 1.70% |
LoseIMVT / S&P IMVT unavailable / 5.02% |
LoseIMVT / S&P IMVT unavailable / 0.21% |
| 2019-Q20/3 |
LoseIMVT / S&P IMVT unavailable / 4.30% |
LoseIMVT / S&P IMVT unavailable / 6.64% |
LoseIMVT / S&P IMVT unavailable / 8.65% |
| 2019-Q10/3 |
LoseIMVT / S&P IMVT unavailable / 13.65% |
LoseIMVT / S&P IMVT unavailable / 8.12% |
LoseIMVT / S&P IMVT unavailable / 14.29% |
| 2018-Q40/3 |
LoseIMVT / S&P IMVT unavailable / -13.52% |
LoseIMVT / S&P IMVT unavailable / 9.05% |
LoseIMVT / S&P IMVT unavailable / 18.23% |
| 2018-Q30/3 |
LoseIMVT / S&P IMVT unavailable / 7.71% |
LoseIMVT / S&P IMVT unavailable / 10.21% |
LoseIMVT / S&P IMVT unavailable / 19.06% |
| 2018-Q20/3 |
LoseIMVT / S&P IMVT unavailable / 3.43% |
LoseIMVT / S&P IMVT unavailable / 9.03% |
LoseIMVT / S&P IMVT unavailable / 14.46% |
| 2018-Q10/3 |
LoseIMVT / S&P IMVT unavailable / -0.76% |
LoseIMVT / S&P IMVT unavailable / 7.68% |
LoseIMVT / S&P IMVT unavailable / 12.46% |
| 2017-Q40/3 |
LoseIMVT / S&P IMVT unavailable / 6.64% |
LoseIMVT / S&P IMVT unavailable / 7.03% |
LoseIMVT / S&P IMVT unavailable / 13.82% |
| 2017-Q30/3 |
LoseIMVT / S&P IMVT unavailable / 4.48% |
LoseIMVT / S&P IMVT unavailable / 5.68% |
LoseIMVT / S&P IMVT unavailable / 17.57% |
| 2017-Q20/3 |
LoseIMVT / S&P IMVT unavailable / 3.09% |
LoseIMVT / S&P IMVT unavailable / 4.83% |
LoseIMVT / S&P IMVT unavailable / 17.74% |
| 2017-Q10/3 |
LoseIMVT / S&P IMVT unavailable / 6.07% |
LoseIMVT / S&P IMVT unavailable / 3.67% |
LoseIMVT / S&P IMVT unavailable / 13.32% |
| 2016-Q40/3 |
LoseIMVT / S&P IMVT unavailable / 3.82% |
LoseIMVT / S&P IMVT unavailable / 2.09% |
LoseIMVT / S&P IMVT unavailable / 7.05% |
| 2016-Q30/3 |
LoseIMVT / S&P IMVT unavailable / 3.85% |
LoseIMVT / S&P IMVT unavailable / 0.20% |
LoseIMVT / S&P IMVT unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | IMVT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 198.30% | 20.78% |
| Annualized return | 198.30% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | IMVT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 396.83% | 83.14% |
| Annualized return | 37.80% | 12.86% |
10Y · 2019-06-21 to 2026-08-27
| Metric | IMVT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 340.40% | 319.30% |
| Annualized return | 15.98% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |